Insulin-like Growth Factor Binding Protein 3 Promoter Variant (rs2854744) is Associated with Nonalcoholic Fatty Liver Disease

Overview

Journal Arch Endocrinol Metab

Specialty Endocrinology

Date 2023 Nov 10

PMID 37948568

Authors

Touraj Mahmoudi

Shadi Nouri

Fatemeh Zarei

Zeinab Nourmohammadi Najafabadi

Maryam Sanei

Shiva Sayedsalehi

Gholamreza Rezamand

Asadollah Asadi

Reza Dabiri

Hossein Nobakht

Hamid Farahani

Seidamir Pasha Tabaeian

Mohammad Reza Zali

Affiliations

Soon will be listed here.

Abstract

Objective: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease and a growing global epidemic. In NAFLD, liver fat surpasses 5% of hepatocytes without the secondary causes of lipid accumulation or excessive alcohol consumption. Given the link between NAFLD and insulin resistance, the possible association between the rs2854744 (-202 G>T) promoter polymorphism of insulin-like growth factor binding protein 3 () gene and NAFLD was investigated in this study.

Materials And Methods: In this genetic case-control association study, the rs2854744 genotypes of 315 unrelated individuals, including 156 patients with biopsy-proven NAFLD and 159 controls, were determined using polymerase chain reaction/restriction fragment length polymorphism analyses.

Results: The "GT+TT" genotype of the rs2854744 polymorphism, compared with the "GG" genotype, was associated with a 2.7-fold increased risk of NAFLD after adjustment for confounding factors (P = 0.009; odds ratio [OR] = 2.71; 95% confidence interval [CI] = 1.19-3.18). Additionally, the IGFBP3 rs2854744 "T" allele, in comparison with the "G" allele, was significantly overrepresented in NAFLD patients than the controls (P = 0.008; OR = 1.85; 95%CI = 1.23-2.94).

Conclusion: Our findings first indicated that the rs2854744 "GT+TT" genotype is a marker of increased NAFLD susceptibility; however, it needs to be supported by further investigations in other populations.

Citing Articles

Association of gene Pro512Ala polymorphism with nonalcoholic fatty liver disease.

Asadi A, Rostami M, Shafiee R, Ardalani A, Dehghanitafti A, Golshadi Z Arch Endocrinol Metab. 2024; 68:e230216.

PMID: 39420901 PMC: 11460970. DOI: 10.20945/2359-4292-2023-0216.

The rs1862513 promoter variant of resistin gene influences susceptibility to nonalcoholic fatty liver disease.

Nouri S, Navari M, Shafiee R, Mahmoudi T, Rezamand G, Asadi A Rev Assoc Med Bras (1992). 2024; 70(7):e20231537.

PMID: 39045929 PMC: 11262324. DOI: 10.1590/1806-9282.20231537.

NAMPT gene rs2058539 variant is a risk factor for nonalcoholic fatty liver disease.

Nouri S, Navari M, Zarei F, Rostami M, Mahmoudi T, Rezamand G Rev Assoc Med Bras (1992). 2024; 70(7):e20230188.

PMID: 39045924 PMC: 11262317. DOI: 10.1590/1806-9282.20230188.

References

Gao M, Zhu B, Li P, Zhang G, Chen K, Lv H . Influence of the -202A/C Gene Polymorphism on Clinical Features and Surgery Outcome in Acromegalic Patients. Front Endocrinol (Lausanne). 2019; 9:751. PMC: 6297192. DOI: 10.3389/fendo.2018.00751. View

Polyzos S, Perakakis N, Boutari C, Kountouras J, Ghaly W, Anastasilakis A . Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. J Clin Endocrinol Metab. 2019; 105(3). PMC: 7112980. DOI: 10.1210/clinem/dgz172. View

Nobakht H, Mahmoudi T, Sabzikarian M, Tabaeian S, Rezamand G, Asadi A . INSULIN AND INSULIN RECEPTOR GENE POLYMORPHISMS AND SUSCEPTIBILITY TO NONALCOHOLIC FATTY LIVER DISEASE. Arq Gastroenterol. 2020; 57(2):203-208. DOI: 10.1590/S0004-2803.202000000-39. View

Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J . Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest. 1996; 98(11):2612-5. PMC: 507720. DOI: 10.1172/JCI119081. View

Gholam P, Flancbaum L, Machan J, Charney D, Kotler D . Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007; 102(2):399-408. DOI: 10.1111/j.1572-0241.2006.01041.x. View

Yao Y, Miao X, Zhu D, Li D, Zhang Y, Song C . Insulin-like growth factor-1 and non-alcoholic fatty liver disease: a systemic review and meta-analysis. Endocrine. 2019; 65(2):227-237. DOI: 10.1007/s12020-019-01982-1. View

Runchey S, Boyko E, Ioannou G, Utzschneider K . Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States. J Gastroenterol Hepatol. 2014; 29(3):589-96. PMC: 3982202. DOI: 10.1111/jgh.12437. View

Li M, Zhang S, Wu Y, Ye J, Cao X, Liu J . Prevalence of Insulin Resistance in Subjects with Nonalcoholic Fatty Liver Disease and Its Predictors in a Chinese Population. Dig Dis Sci. 2015; 60(7):2170-6. DOI: 10.1007/s10620-015-3564-5. View

Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R . Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol. 2006; 41(5):462-9. DOI: 10.1007/s00535-006-1790-5. View

10.

Ney D, Yang H, Smith S, Unterman T . High-calorie total parenteral nutrition reduces hepatic insulin-like growth factor-I mRNA and alters serum levels of insulin-like growth factor-binding protein-1, -3, -5, and -6 in the rat. Metabolism. 1995; 44(2):152-60. DOI: 10.1016/0026-0495(95)90258-9. View

11.

Sukhanov S, Higashi Y, Shai S, Vaughn C, Mohler J, Li Y . IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2007; 27(12):2684-90. DOI: 10.1161/ATVBAHA.107.156257. View

12.

Stanley T, Fourman L, Zheng I, McClure C, Feldpausch M, Torriani M . Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2020; 106(2):e520-e533. PMC: 7823253. DOI: 10.1210/clinem/dgaa792. View

13.

Mirakholi M, Mahmoudi T, Heidari M . MicroRNAs horizon in retinoblastoma. Acta Med Iran. 2014; 51(12):823-9. View

14.

Mahmoudi T, Majidzadeh-A K, Karimi K, Karimi N, Farahani H, Dabiri R . An exon variant in insulin receptor gene is associated with susceptibility to colorectal cancer in women. Tumour Biol. 2015; 36(5):3709-15. DOI: 10.1007/s13277-014-3010-x. View

15.

Volzke H, Nauck M, Rettig R, Dorr M, Higham C, Brabant G . Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur J Endocrinol. 2009; 161(5):705-13. DOI: 10.1530/EJE-09-0374. View

16.

Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N . Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev. 2001; 10(4):377-84. View

17.

Miller M, Walsh S, Atrih A, Huang J, Ferguson M, Dillon J . Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2014; 29(10):1839-47. DOI: 10.1111/jgh.12614. View

18.

Sabzikarian M, Mahmoudi T, Tabaeian S, Rezamand G, Asadi A, Farahani H . The common variant of rs6214 in insulin like growth factor 1 () gene: a potential protective factor for non-alcoholic fatty liver disease. Arch Physiol Biochem. 2020; 129(1):10-15. DOI: 10.1080/13813455.2020.1791187. View

19.

Fusco A, Miele L, DUonnolo A, Forgione A, Riccardi L, Cefalo C . Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clin Endocrinol (Oxf). 2011; 77(4):531-6. DOI: 10.1111/j.1365-2265.2011.04291.x. View

20.

Bellentani S, Scaglioni F, Marino M, Bedogni G . Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010; 28(1):155-61. DOI: 10.1159/000282080. View